Compare Summit Therapeutics Inc (SMMT) vs iShares TIPS Bond ETF (TIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs iShares TIPS Bond ETF — how do they compare? Summit Therapeutics Inc trades at $17.52 (market cap $13.79B), while iShares TIPS Bond ETF trades at $106.82. The key difference: Summit Therapeutics Inc is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals.
| SMMT | TIP | |
|---|---|---|
Market Cap | $13.79B | — |
Sector | Health | Fixed Income |
52-Week High | $26.38 | $112.20 |
52-Week Low | $12.43 | $106.77 |
Enterprise Value | $13.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
TIP trades at $107.05 with minimal daily movement (+0.07%), showing stability amid broader market volatility. Technical indicators signal a bearish trend with moving averages and overall momentum favoring sellers. The company has announced upcoming dividends totaling $1.84 per share for H2-2026, providing income appeal. Recent news highlights Treasury market volatility and inflation concerns that may impact bond-related equities.
The stock faces headwinds from bearish technical momentum and macroeconomic uncertainty around interest rates. Dividend payments offer some support, but limited fundamental data availability requires careful monitoring of upcoming financial disclosures for clearer valuation assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About iShares TIPS Bond ETF
TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →
